CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Dr Falk Pharma against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 28, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Corticosteroid CompositionsMERITAGE PHARMASep 1, 2022
Methods Of Treatment For Esophageal InflammationMERITAGE PHARMAMay 4, 2022
Rapidly Dispersing Granules, Orally Disintegrating Tablets And MethodsADARE PHARMACEUTICALSFeb 23, 2021
Compositions For The Treatment Of Gastrointestinal InflammationMERITAGE PHARMASep 23, 2020
Corticosteroid Containing Orally Disintegrating Tablet Compositions For Eosinophilic EsophagitisADARE IJul 22, 2020
Orally Administered Corticosteroid CompositionsADARE IApr 28, 2020
Corticosteroid CompositionsMERITAGE PHARMADec 19, 2019
Orally Administered Corticosteroid CompositionsADARE IMar 1, 2019
Compositions For The Treatment Of Gastrointestinal InflammationMERITAGE PHARMASep 27, 2018
Compositions For The Treatment Of Inflammation Of The Gastrointestinal TractMERITAGE PHARMAMay 22, 2018

Explore Dr Falk Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 28, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 2, 2022Optimised Pharmaceutical Formula For The Treatment Of Inflammatory Changes Of The Esophagus1
Sep 26, 2018Optimized Pharmaceutical Formulation For The Treatment Of Inflammatory Conditions Of The Esophagus1